Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Summaries for Patients |4 December 2007

Antiviral Therapy for Chronic Hepatitis B Free

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information

  • The summary below is from the full report titled “Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis with Telbivudine or Adefovir. A Randomized Trial.” It is in the 4 December 2007 issue of Annals of Internal Medicine (volume 147, pages 745-754). The authors are H.L.Y. Chan, E.J. Heathcote, P. Marcellin, C.L. Lai, M. Cho, Y.M. Moon, Y.C. Chao, R.P. Myers, G.Y. Minuk, L. Jeffers, W. Sievert, N. Bzowej, G. Harb, R. Kaiser, X.J. Qiao, N.A. Brown, and the 018 Study Group.


Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
    • What is the problem and what is known about it so far?
    • Why did the researchers do this particular study?
    • Who was studied?
    • How was the study done?
    • What did the researchers find?
    • What were the limitations of the study?
    • What are the implications of the study?
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link

What is the problem and what is known about it so far?

Hepatitis B is inflammation of the liver that is caused by a virus. The virus spreads through contact with infected body fluids. Most people who get hepatitis B recover within a few months, but some develop chronic infection. Chronic infection increases risk for liver failure and liver cancer. Persons with chronic infection often have virus-related protein substances in their blood (called hepatitis B surface antigens and e antigens) for many years. When an e antigen is present, it usually means that the person has very active liver disease and a lot of virus present. Doctors often treat these patients with powerful antiviral drugs. However, some patients develop viral forms (mutants) that are resistant to 1 or more antiviral drugs. To help suppress virus levels, prevent resistance, and improve outcomes, doctors might use different types of antiviral drugs or switch drugs during treatment. Few studies have assessed the benefits and harms of switching among different antiviral therapies for chronic hepatitis B.

Why did the researchers do this particular study?

To see which of the following 3 treatment regimens best suppresses virus levels in patients with chronic hepatitis B: telbivudine (a thymidine nucleoside analogue), adefovir (an adenosine nucleotide analogue), or adefovir followed by a switch to telbivudine.

Who was studied?

135 adults with chronic hepatitis B who were e antigen positive. Their average age was about 33 years. Most were Asian men. None were co-infected with hepatitis C or D virus or HIV.

How was the study done?

The researchers recruited patients with e antigen–positive chronic hepatitis B from 16 international, academic, gastroenterology clinics. Patients were randomly assigned to telbuvidine for 52 weeks, adefovir for 52 weeks, or adefovir for 24 weeks followed by a switch to telbivudine for 28 weeks. Telbuvidine was taken as 3 daily pills (600 mg total) and adefovir as a single daily pill (10 mg). The researchers asked patients about side effects and tested blood for evidence of actively multiplying virus (HBV DNA levels) several times during follow-up. They then compared the amounts of virus over time in the groups.

What did the researchers find?

Tests at 24 weeks after treatment showed that viral amounts (HBV DNA levels) were reduced more with telbuvidine than with adefovir. At 52 weeks, HBV DNA levels were similar among patients initially treated with telbivudine and among those switched to telbivudine. These levels were lower than those among patients treated continuously with adefovir. Similar types and numbers of side effects were reported across groups.

What were the limitations of the study?

Both the researchers and the patients knew which therapies the patients received. Long-term drug resistance and clinical outcomes were not assessed. We do not yet know whether the findings are generalizable to other geographic areas and populations. Only 2 of several available antiviral agents were tested.

What are the implications of the study?

Telbivudine alone and switching from adefovir to telbivudine both suppressed viral levels more than adefovir alone in adults with e antigen–positive chronic hepatitis B.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Antiviral Therapy for Chronic Hepatitis B. Ann Intern Med. 2007;147:I–16. doi: https://doi.org/10.7326/0003-4819-147-11-200712040-00184

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2020

×
Permissions

Published: Ann Intern Med. 2007;147(11):I-16.

DOI: 10.7326/0003-4819-147-11-200712040-00184

©
2007 American College of Physicians
0 Citations
Advertisement

See Also
Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis with Telbivudine or Adefovir: A Randomized Trial
View MoreView Less

Related Articles
Review: Evidence is insufficient to evaluate effectiveness of antiviral therapies for chronic hepatitis B
Annals of Internal Medicine; 150 (10): JC5-6
Antiviral Regimens for Chronic Hepatitis B Virus Infection
Annals of Internal Medicine; 142 (10): I-39
Remission of Psoriasis After Treatment of Chronic Hepatitis C Virus Infection With Direct-Acting Antivirals
Annals of Internal Medicine; 168 (9): 678-680
Benefits of Direct-Acting Antivirals for Hepatitis C
Annals of Internal Medicine; 167 (11): 812-813
View MoreView Less

Journal Club
Review: Evidence is insufficient to evaluate effectiveness of antiviral therapies for chronic hepatitis B
Annals of Internal Medicine; 150 (10): JC5-6
Review: In chronic hepatitis C virus infection, oral direct-acting antivirals have high sustained virologic response
Annals of Internal Medicine; 167 (2): JC3
Review: Oral antiviral drugs reduce clinical recurrence in recurrent genital herpes
Annals of Internal Medicine; 162 (4): JC7
Review: Neuraminidase inhibitors reduce symptomatic influenza; oseltamivir does not reduce hospitalizations
Annals of Internal Medicine; 161 (8): JC2
View MoreView Less

Related Point of Care
Hepatitis C Virus
Annals of Internal Medicine; 165 (5): ITC33-ITC48
Influenza
Annals of Internal Medicine; 167 (5): ITC33-ITC48
View MoreView Less

Related Topics
Gastroenterology/Hepatology
Infectious Disease
Liver Disease
Viral Hepatitis

Gastroenterology/Hepatology, Infectious Disease, Liver Disease, Viral Hepatitis.

PubMed Articles
Detection of hepatitis B virus infection in German blood donors 2008-2015.
Vox Sang 2020.
Synthesis of Four Optical Isomers of Antiviral Agent NK0209 and Determination of Their Configurations and Activities against a Plant Virus.
J Agric Food Chem 2020.
View More

Results provided by: PubMed

Advertisement
CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2020 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×